Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’
Topline Phase III Data Showed Mixed Induction Results, Maintenance Miss
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
